|
|
Volumn 49, Issue 4, 2010, Pages 767-777
|
|
Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIRHEUMATIC AGENT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
RITUXIMAB;
TUMOR NECROSIS FACTOR;
ADULT;
ARTICLE;
BIOLOGICAL MODEL;
COHORT ANALYSIS;
COST BENEFIT ANALYSIS;
DRUG ANTAGONISM;
ECONOMICS;
FEMALE;
FINLAND;
HEALTH CARE COST;
HOSPITALIZATION;
HUMAN;
MALE;
MIDDLE AGED;
QUALITY ADJUSTED LIFE YEAR;
RHEUMATOID ARTHRITIS;
TIME;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
COHORT STUDIES;
COST-BENEFIT ANALYSIS;
FEMALE;
FINLAND;
HEALTH CARE COSTS;
HUMANS;
MALE;
MIDDLE AGED;
MODELS, BIOLOGICAL;
QUALITY-ADJUSTED LIFE YEARS;
SEVERITY OF ILLNESS INDEX;
TIME FACTORS;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTORS;
|
|
EID: 79952471147
PISSN: None
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/kep425 Document Type: Article |
|
Times cited : (50)
|
|
References (0)
|
